trending Market Intelligence /marketintelligence/en/news-insights/trending/-Y9SqqkrVI7vMCPFkZ5W0g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Roche's Avastin combo wins US FDA nod for expanded use in ovarian cancer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Roche's Avastin combo wins US FDA nod for expanded use in ovarian cancer

The U.S. Food and Drug Administration approved a combination of Roche Holding AG's blockbuster medicine Avastin and chemotherapy for treating women with advanced ovarian cancer who had undergone surgery.

Avastin, which recorded sales of about CHF6.7 billion in 2017, is now approved in the U.S. for 10 uses across six types of cancer.

The Basel, Switzerland-based pharmaceuticals giant said the U.S. regulator approved Avastin to be used in combination with chemotherapy drugs carboplatin and paclitaxel, followed by Avastin alone, for treating women with stage 3 or stage 4 epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgery.

Roche unit Genentech Inc., which submitted the biologics license application to the U.S. regulator in October 2017, said the approval was based on data from its phase 3 trial, named GOG-0218, which showed that patients on the Avastin and chemotherapy combination, followed by continued use of Avastin alone, lived for a median of 18.2 months without the disease progressing, compared to 12 months for those who just received chemotherapy.

Avastin is also being evaluated in combination with other medicines to treat certain other cancer types.

At the American Society of Clinical Oncology meeting Roche said the combination regimen of its drugs Tecentriq and Avastin along with chemotherapy stopped cancer from growing in certain lung cancer patients.